Abstract
The ongoing pandemic of COVID-19 has aroused widespread concern around the world and poses a severe threat to public health worldwide. In this paper, the autoregressive integrated moving average (ARIMA) model was used to predict the epidemic trend of COVID-19 in mainland of China. We collected the cumulative cases, cumulative deaths, and cumulative recovery in mainland of China from January 20 to June 30, 2020, and divided the data into experimental group and test group. The ARIMA model was fitted with the experimental group data, and the optimal model was selected for prediction analysis. The predicted data were compared with the test group. The average relative errors of actual cumulative cases, deaths, recovery and predicted values in each province are between −22.32%−22.66%, −9.52%−0.08%, −8.84%−1.16, the results of the comprehensive experimental group and test group show The error of fitting and prediction is small, the degree of fitting is good, the model supports and is suitable for the prediction of the epidemic situation, which has practical guiding significance for the prevention and control of the epidemic situation.
Highlights:
We predicted future COVID-19 occurrences in mainland of China based on ARIMA model.
We validated the model based on the previous outbreak data with actual data for June, 2020.
The measures taken by the government have contained spread of the epidemic
The combination of multiple models may improve the robustness of the model
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Natural Science Foundation of China Spatial data analysis and geoscientific calculation are used to study urban vulnerability based on microgeographic units(grant numbers: 41461035).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication. I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part. All the authors listed have approved the manuscript that is enclosed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵1 Chuqiao Hana and Xifeng Ju are co-first authors of the article.
Data Availability
The COVID-19 case data comes from the National and local health and construction commission daily information release (https://ncov.dxy.cn/).
